These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23238902)

  • 1. Pharmacological conversion of atrial fibrillation in the patients of Graves' disease.
    Kunii Y; Uruno T; Matsumoto M; Mukasa K; Noh J; Ito K; Akaishi M; Hori S; Nakazawa H
    Tokai J Exp Clin Med; 2012 Dec; 37(4):107-12. PubMed ID: 23238902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial.
    Yamase M; Nakazato Y; Daida H
    Heart; 2012 Jul; 98(14):1067-71. PubMed ID: 22689712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between inflammation state and successful medical cardioversion using bepridil for refractory atrial fibrillation.
    Nishino M; Mori N; Nakamura D; Lee Y; Yoshimura T; Taniike M; Makino N; Kato H; Egami Y; Shutta R; Tanouchi J; Yamada Y
    J Cardiol; 2013 Aug; 62(2):117-20. PubMed ID: 23623817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation.
    Kawamura M; Ito H; Onuki T; Miyoshi F; Minoura Y; Asano T; Tanno K; Kobayashi Y
    J Cardiol; 2007 Dec; 50(6):343-50. PubMed ID: 18186308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.
    Fujiki A; Tsuneda T; Sugao M; Mizumaki K; Inoue H
    Am J Cardiol; 2003 Aug; 92(4):472-5. PubMed ID: 12914884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation.
    Aoyama Y; Niwano S; Niwano H; Satoh A; Kishihara J; Ishikawa S; Murakami M; Fukumoto K; Ueno K; Izumi T
    Int Heart J; 2011; 52(6):353-8. PubMed ID: 22188708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).
    Yamashita T; Ogawa S; Sato T; Aizawa Y; Atarashi H; Fujiki A; Inoue H; Ito M; Katoh T; Kobayashi Y; Koretsune Y; Kumagai K; Niwano S; Okazaki O; Okumura K; Saku K; Tanabe T; Origasa H;
    Circ J; 2009 Jun; 73(6):1020-7. PubMed ID: 19359813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
    Kawamura M; Munetsugu Y; Tanno K; Kobayashi Y
    J Cardiovasc Pharmacol; 2013 Jan; 61(1):77-82. PubMed ID: 23107870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation.
    Fujiki A; Tsuneda T; Sakabe M; Nakagawa K; Mizumaki K; Hirai T; Inoue H
    Circ J; 2004 Sep; 68(9):834-9. PubMed ID: 15329504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation.
    Miyazaki S; Kuwahara T; Kobori A; Takahashi Y; Takei A; Sato A; Isobe M; Takahashi A
    Europace; 2009 Dec; 11(12):1620-3. PubMed ID: 19910313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation.
    Kawamura M; Ito H; Onuki T; Miyoshi F; Watanabe N; Asano T; Tanno K; Kobayashi Y
    J Cardiovasc Pharmacol; 2010 May; 55(5):511-7. PubMed ID: 20164787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine.
    Fujiki A; Sakabe M; Nishida K; Sugao M; Tsuneda T; Iwamoto J; Mizumaki K; Inoue H
    Circ J; 2004 Dec; 68(12):1139-45. PubMed ID: 15564697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation.
    Siu CW; Jim MH; Zhang X; Chan YH; Pong V; Kwok J; Kung AW; Lau CP; Tse HF
    Am J Cardiol; 2009 Feb; 103(4):540-3. PubMed ID: 19195517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation.
    Shamoto A; Chishaki A; Tsuchihashi-Makaya M; Chishaki H; Takemoto M; Mukai Y; Inoue S; Sunagawa K
    J Cardiovasc Med (Hagerstown); 2012 Nov; 13(11):747-54. PubMed ID: 22914308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological cardioversion of long-lasting atrial fibrillation.
    Fujiki A; Inoue H
    Circ J; 2007; 71 Suppl A():A69-74. PubMed ID: 17587743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation.
    Fujiki A; Sakamoto T; Nishida K; Mizumaki K; Inoue H
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):264-6. PubMed ID: 17878753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
    Imai S; Saito F; Takase H; Enomoto M; Aoyama H; Yamaji S; Yokoyama K; Yagi H; Kushiro T; Hirayama A
    Circ J; 2008 May; 72(5):709-15. PubMed ID: 18441448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological rhythm control strategy for atrial fibrillation].
    Sasano T; Hirao K
    Nihon Rinsho; 2013 Jan; 71(1):67-71. PubMed ID: 23631174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.